Actively Recruiting
Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)
Led by Instituto Sistemas Complejos de Ingeniería · Updated on 2024-07-22
160000
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The Nirse-CL study is a collaborative effort between the Ministry of Health of Chile, Instituto Sistemas Complejos de Ingeniería (ISCI), and the Faculty of Medicine of the University of Chile. The primary aim is to determine the effectiveness of the monoclonal antibody nirsevimab in preventing RSV infection in infants based on the integrated analysis of several national databases before, during, and after the implementation of a universal immunization program. The impact of the program on RSV-related health outcomes will also be determined.
CONDITIONS
Official Title
Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Born between October 1, 2023, and September 31, 2024
- Born with 29 weeks of gestational age or less between July 1, 2023, and October 1, 2023
- Born with Bronchopulmonary Dysplasia (BPD), 32 or less weeks gestational age and/or birth weight less than 1.75 kgs between April 1, 2023, and October 1, 2023
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
ISCI
Santiago, Chile, 8370398
Actively Recruiting
Research Team
L
Leonardo Basso, PhD in Business Administration
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here